Histogenics Cp Cmn (HSGX) 3.29 $HSGX Histogenic
Post# of 273254
Posted On: 09/21/2016 7:17:40 AM
Histogenics Cp Cmn (HSGX) 3.29 $HSGX
Histogenics Corporation Announces $30.0 Million Private Placement
GlobeNewswire - Fri Sep 16, 5:30AM CDT
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that it has entered into a definitive securities purchase agreement to raise approximately $30.0 million in a private placement of common stock, Series A Convertible Preferred Stock and warrants exercisable for common stock. The private placement is being led by new healthcare dedicated institutional investors, with participation by certain existing investors.
HSGX: 3.29 (+0.22)
Histogenics Corporation to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Wed Aug 31, 7:30AM CDT
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will present at the 18 Annual Rodman & Renshaw Global Investment Conference on Monday, September 12, 2016 at 11:40 AM EDT. The conference is sponsored by H.C. Wainwright & Co., LLC., and will be held September 11-13, 2016 at the Lotte New York Palace Hotel in New York City.
HSGX: 3.29 (+0.22)
Histogenics Corporation Announces Second Quarter 2016 Financial and Operating Results
GlobeNewswire - Thu Aug 11, 5:30AM CDT
- NeoCart(R) Phase 3 Clinical Trial Remains on Track for Enrollment
HSGX: 3.29 (+0.22)
Histogenics Corporation to Announce Second Quarter 2016 Financial Results on August 11, 2016
GlobeNewswire - Thu Jul 28, 7:30AM CDT
Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter ended June 30, 2016 on August 11, 2016 before the market opens.
HSGX: 3.29 (+0.22)
Histogenics reports 1Q loss
Automated Insights - Thu May 12, 5:41AM CDT
WALTHAM, Mass. (AP) _ Histogenics Corp. (HSGX) on Thursday reported a loss of $7.9 million in its first quarter.
HSGX: 3.29 (+0.22)
Histogenics Corporation Announces First Quarter 2016 Financial and Operating Results
GlobeNewswire - Thu May 12, 5:30AM CDT
- NeoCart(R) Phase 3 Clinical Trial Remains on Track for Enrollment Completion by End of Second Quarter of 2017 -
HSGX: 3.29 (+0.22)
Histogenics Corporation Acquires NeoCart(R) Development and Commercialization Rights for Japanese Market
GlobeNewswire - Tue May 10, 8:00AM CDT
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced that it has acquired the development and commercialization rights to NeoCart for the Japanese market from its long-time development partner Purpose Co., Ltd (Purpose). This agreement is the next step in Histogenics' strong and evolving relationship with Purpose and provides Histogenics the opportunity to capitalize on the recent advancements in regenerative medicine regulatory pathways in Japan.
HSGX: 3.29 (+0.22)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Histogencis Corporation -- HSGX
PR Newswire - Wed May 04, 4:32PM CDT
Levi & Korsinsky announces it has commenced an investigation of Histogenics Corporation (NASDAQ: HSGX) concerning possible breaches of fiduciary duty by its Board of Directors. To obtain additional information, GO TO: http://zlk.9nl.com/histogenics-hsgx or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
HSGX: 3.29 (+0.22)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Histogenics Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Wed May 04, 10:20AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Histogenics Corporation (NASDAQ:HSGX).
HSGX: 3.29 (+0.22)
Histogenics Corporation to Announce First Quarter 2016 Financial Results on May 12, 2016
GlobeNewswire - Thu Apr 28, 7:30AM CDT
Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter ended March 31, 2016 on May 12, 2016 before the market opens.
HSGX: 3.29 (+0.22)
Histogenics Corporation Provides NeoCart(R) Phase 3 Clinical Trial Enrollment Update
GlobeNewswire - Tue Feb 02, 3:06PM CST
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced that as of February 2, 2016 it had enrolled 123, or just over half, of the 245 patients required to complete enrollment of its ongoing NeoCart Phase 3 clinical trial. This trial is being conducted under a Special Protocol Assessment (SPA) with the United States Food and Drug Administration (FDA).
HSGX: 3.29 (+0.22)
Histogenics Corporation to Present at 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Jan 26, 7:31AM CST
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will be presenting at the 18 Annual BIO CEO & Investor Conference on Tuesday February 9, 2016 at 3:30PM EST during the conference's Regenerative Medicine track at the Waldorf Astoria in New York, NY. The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.
HSGX: 3.29 (+0.22)
Histogenics Corporation to Present at Biotech Showcase 2016
GlobeNewswire - Wed Jan 06, 7:30AM CST
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will present at the 8 Annual Biotech Showcase(TM) Conference on Monday, January 11, 2016 at 11:30 AM PST at the Parc 55 Hotel in San Francisco, CA.
HSGX: 3.29 (+0.22)
Histogenics Corporation Announces Amendment to NeoCart(R) Phase 3 Clinical Trial Enrollment Criteria
GlobeNewswire - Mon Dec 21, 7:15AM CST
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced that the United States Food and Drug Administration (FDA) has accepted the Company's amendment filed in November 2015 to the NeoCart Phase 3 clinical trial protocol to expand the eligible patient population. The approved protocol amendment was submitted, and the clinical trial is being conducted under, a Special Protocol Assessment (SPA) with the FDA.
HSGX: 3.29 (+0.22)
Articular Cartilage Defect Global Clinical Trials Review, H2, 2015 - Analysis, Trends, Technologies & Forecasts
M2 - Wed Dec 09, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdgh96/articular) has announced the addition of the "Articular Cartilage Defect Global Clinical Trials Review, H2, 2015" report to their offering. Our clinical trial report, Articular Cartilage Defect Global Clinical Trials Review, H2, 2015" provides an overview of Articular Cartilage Defect clinical trials scenario. This report provides top line data relating to the clinical trials on Articular Cartilage Defect. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - MediPost Co., Ltd. - Zimmer Biomet Holdings, Inc. - Vericel Corporation - B. Braun Melsungen AG - Sewon Corporation Co., Ltd. - Sanofi - Histogenics Corporation - Co.don AG - Bone & Joint Clinic of Baton Rouge, Inc. - Banc de Sang i Teixits For more information visit http://www.researchandmarkets.com/research/xdgh96/articular
HSGX: 3.29 (+0.22), ZBH: 124.79 (-0.18), VCEL: 2.37 (unch)
Histogenics Corporation Announces Third Quarter 2015 Financial and Operating Results
GlobeNewswire - Thu Nov 12, 5:30AM CST
- Completion of Enrollment of NeoCart(R) Phase 3 Trial Now Expected in Second Quarter of 2017 -
HSGX: 3.29 (+0.22)
VirMedica Appoints John H. Johnson as Executive Chairman of the Board of Directors
PR Newswire - Mon Nov 09, 6:00AM CST
VirMedica, the leader in providing e-access technology solutions designed to expedite patient access to biopharmaceutical products, today announced the appointment of John H. Johnson as executive chairman of the Company's Board of Directors, effectively immediately.
JNJ: 117.95 (+0.29), HSGX: 3.29 (+0.22), PTLA: 23.48 (+0.40), PFE: 33.81 (+0.16), LLY: 79.88 (+0.72), SBBP: 4.80 (+0.29)
Histogenics Corporation to Announce Third Quarter 2015 Financial Results on November 12, 2015
GlobeNewswire - Thu Oct 29, 7:30AM CDT
Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the third quarter ended September 30, 2015 on November 12, 2015 before the market opens.
HSGX: 3.29 (+0.22)
Histogenics Corporation to Participate in Upcoming Scientific and Investor Conferences
GlobeNewswire - Thu Oct 01, 8:23AM CDT
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be participating in four upcoming conferences.
HSGX: 3.29 (+0.22)
Histogenics Corporation Announces $30.0 Million Private Placement
GlobeNewswire - Fri Sep 16, 5:30AM CDT
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that it has entered into a definitive securities purchase agreement to raise approximately $30.0 million in a private placement of common stock, Series A Convertible Preferred Stock and warrants exercisable for common stock. The private placement is being led by new healthcare dedicated institutional investors, with participation by certain existing investors.
HSGX: 3.29 (+0.22)
Histogenics Corporation to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Wed Aug 31, 7:30AM CDT
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will present at the 18 Annual Rodman & Renshaw Global Investment Conference on Monday, September 12, 2016 at 11:40 AM EDT. The conference is sponsored by H.C. Wainwright & Co., LLC., and will be held September 11-13, 2016 at the Lotte New York Palace Hotel in New York City.
HSGX: 3.29 (+0.22)
Histogenics Corporation Announces Second Quarter 2016 Financial and Operating Results
GlobeNewswire - Thu Aug 11, 5:30AM CDT
- NeoCart(R) Phase 3 Clinical Trial Remains on Track for Enrollment
HSGX: 3.29 (+0.22)
Histogenics Corporation to Announce Second Quarter 2016 Financial Results on August 11, 2016
GlobeNewswire - Thu Jul 28, 7:30AM CDT
Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter ended June 30, 2016 on August 11, 2016 before the market opens.
HSGX: 3.29 (+0.22)
Histogenics reports 1Q loss
Automated Insights - Thu May 12, 5:41AM CDT
WALTHAM, Mass. (AP) _ Histogenics Corp. (HSGX) on Thursday reported a loss of $7.9 million in its first quarter.
HSGX: 3.29 (+0.22)
Histogenics Corporation Announces First Quarter 2016 Financial and Operating Results
GlobeNewswire - Thu May 12, 5:30AM CDT
- NeoCart(R) Phase 3 Clinical Trial Remains on Track for Enrollment Completion by End of Second Quarter of 2017 -
HSGX: 3.29 (+0.22)
Histogenics Corporation Acquires NeoCart(R) Development and Commercialization Rights for Japanese Market
GlobeNewswire - Tue May 10, 8:00AM CDT
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced that it has acquired the development and commercialization rights to NeoCart for the Japanese market from its long-time development partner Purpose Co., Ltd (Purpose). This agreement is the next step in Histogenics' strong and evolving relationship with Purpose and provides Histogenics the opportunity to capitalize on the recent advancements in regenerative medicine regulatory pathways in Japan.
HSGX: 3.29 (+0.22)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Histogencis Corporation -- HSGX
PR Newswire - Wed May 04, 4:32PM CDT
Levi & Korsinsky announces it has commenced an investigation of Histogenics Corporation (NASDAQ: HSGX) concerning possible breaches of fiduciary duty by its Board of Directors. To obtain additional information, GO TO: http://zlk.9nl.com/histogenics-hsgx or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
HSGX: 3.29 (+0.22)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Histogenics Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Wed May 04, 10:20AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Histogenics Corporation (NASDAQ:HSGX).
HSGX: 3.29 (+0.22)
Histogenics Corporation to Announce First Quarter 2016 Financial Results on May 12, 2016
GlobeNewswire - Thu Apr 28, 7:30AM CDT
Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter ended March 31, 2016 on May 12, 2016 before the market opens.
HSGX: 3.29 (+0.22)
Histogenics Corporation Provides NeoCart(R) Phase 3 Clinical Trial Enrollment Update
GlobeNewswire - Tue Feb 02, 3:06PM CST
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced that as of February 2, 2016 it had enrolled 123, or just over half, of the 245 patients required to complete enrollment of its ongoing NeoCart Phase 3 clinical trial. This trial is being conducted under a Special Protocol Assessment (SPA) with the United States Food and Drug Administration (FDA).
HSGX: 3.29 (+0.22)
Histogenics Corporation to Present at 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Jan 26, 7:31AM CST
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will be presenting at the 18 Annual BIO CEO & Investor Conference on Tuesday February 9, 2016 at 3:30PM EST during the conference's Regenerative Medicine track at the Waldorf Astoria in New York, NY. The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.
HSGX: 3.29 (+0.22)
Histogenics Corporation to Present at Biotech Showcase 2016
GlobeNewswire - Wed Jan 06, 7:30AM CST
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will present at the 8 Annual Biotech Showcase(TM) Conference on Monday, January 11, 2016 at 11:30 AM PST at the Parc 55 Hotel in San Francisco, CA.
HSGX: 3.29 (+0.22)
Histogenics Corporation Announces Amendment to NeoCart(R) Phase 3 Clinical Trial Enrollment Criteria
GlobeNewswire - Mon Dec 21, 7:15AM CST
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced that the United States Food and Drug Administration (FDA) has accepted the Company's amendment filed in November 2015 to the NeoCart Phase 3 clinical trial protocol to expand the eligible patient population. The approved protocol amendment was submitted, and the clinical trial is being conducted under, a Special Protocol Assessment (SPA) with the FDA.
HSGX: 3.29 (+0.22)
Articular Cartilage Defect Global Clinical Trials Review, H2, 2015 - Analysis, Trends, Technologies & Forecasts
M2 - Wed Dec 09, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdgh96/articular) has announced the addition of the "Articular Cartilage Defect Global Clinical Trials Review, H2, 2015" report to their offering. Our clinical trial report, Articular Cartilage Defect Global Clinical Trials Review, H2, 2015" provides an overview of Articular Cartilage Defect clinical trials scenario. This report provides top line data relating to the clinical trials on Articular Cartilage Defect. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - MediPost Co., Ltd. - Zimmer Biomet Holdings, Inc. - Vericel Corporation - B. Braun Melsungen AG - Sewon Corporation Co., Ltd. - Sanofi - Histogenics Corporation - Co.don AG - Bone & Joint Clinic of Baton Rouge, Inc. - Banc de Sang i Teixits For more information visit http://www.researchandmarkets.com/research/xdgh96/articular
HSGX: 3.29 (+0.22), ZBH: 124.79 (-0.18), VCEL: 2.37 (unch)
Histogenics Corporation Announces Third Quarter 2015 Financial and Operating Results
GlobeNewswire - Thu Nov 12, 5:30AM CST
- Completion of Enrollment of NeoCart(R) Phase 3 Trial Now Expected in Second Quarter of 2017 -
HSGX: 3.29 (+0.22)
VirMedica Appoints John H. Johnson as Executive Chairman of the Board of Directors
PR Newswire - Mon Nov 09, 6:00AM CST
VirMedica, the leader in providing e-access technology solutions designed to expedite patient access to biopharmaceutical products, today announced the appointment of John H. Johnson as executive chairman of the Company's Board of Directors, effectively immediately.
JNJ: 117.95 (+0.29), HSGX: 3.29 (+0.22), PTLA: 23.48 (+0.40), PFE: 33.81 (+0.16), LLY: 79.88 (+0.72), SBBP: 4.80 (+0.29)
Histogenics Corporation to Announce Third Quarter 2015 Financial Results on November 12, 2015
GlobeNewswire - Thu Oct 29, 7:30AM CDT
Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the third quarter ended September 30, 2015 on November 12, 2015 before the market opens.
HSGX: 3.29 (+0.22)
Histogenics Corporation to Participate in Upcoming Scientific and Investor Conferences
GlobeNewswire - Thu Oct 01, 8:23AM CDT
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be participating in four upcoming conferences.
HSGX: 3.29 (+0.22)
(0)
(0)Scroll down for more posts ▼